

Jean Claude Ansquer and Christelle Foucher

Introduction

Peroxisome proliferator-activated receptors (PPARs), a family of cell receptors, are closely involved in glucose and lipoprotein metabolism. As discussed elsewhere in this book, PPAR alpha (PPAR α) agonists, such as fenofibrate, have shown clinical benefit for cardiovascular disease in some subgroups and for the macrovascular and microvascular complications of type 2 diabetes mellitus. This chapter reviews the basic science of the PPAR system and summarizes some clinical PPAR modulating drug trials, with an emphasis on diabetes, lipoproteins, and vascular disease. The chapter is divided into five sections:

1. PPAR gene and gene variants, proteins, and natural ligands
2. Synthetic ligands: from PPAR activators to PPAR agonists
3. The PPAR machinery with subsections on:
 - Coactivators and corepressors
 - Metabolic modification (phosphorylation, ubiquitination, sumoylation, and acetylation)
 - Partial agonists or SPPARMs

4. Effect of PPAR agonists in diabetes:
 - Pharmacology, in particular, in the pancreas
 - Effects in type 1 diabetes
 - Effects in type 2 diabetes and/or dyslipidemia with products reaching clinical development
5. Conclusions and perspectives

PPAR Gene and Gene Variants, Proteins, and Natural Ligands

Peroxisome proliferator-activated receptors (PPARs) belong to a subfamily of the nuclear receptors which includes the retinoic acid receptors, the thyroid hormone receptors, and the RevErbA-related orphan receptors [1]. The PPAR subfamily contains three isoforms, namely, PPAR α (PPARA, NR1C1), PPAR β/δ (NR1C2 identified here as PPAR δ), and PPAR γ (PPARG, NR1C3, PPAR γ 1, and PPAR γ 2 sub-isoforms), that are encoded by different genes on different chromosomes.

In humans, PPAR α is mapped on chromosome 22 on the regions 22q12-q13.1; 22q13.31 with a linkage group of six genes and genetic markers [2]. The human PPAR γ gene is located on chromosome 3 at position 3p25, close to the retinoic acid receptor beta (RAR β) and the thyroid hormone receptor beta genes [3–5]. Two different human PPAR γ transcripts are expressed in hematopoietic cells: a 1.85-kb transcript, which corresponds to the full-length mRNA (PPAR γ 1), and a shorter 0.65-kb transcript (PPAR γ 2) [5].

J.C. Ansquer, M.D. • C. Foucher, Ph.D. (✉)
ClinSciences, 10 avenue Victor Hugo,
21000 Dijon, France
e-mail: jean-claude.ansquer@clinsciences.fr




Fig. 19.1 Structure of PPARs. In the *upper panel*, the structure of PPARs with their four domains: 1 is the NH₂ terminal and 468 the COOH terminal for PPAR α . The *bottom panel* illustrates the relative activation for PPAR α

and PPAR γ for major agonists with fenofibrate and rosiglitazone as behaving as specific activators and aleglitazar or pioglitazone with mixed effects

PPAR γ 2 is mostly expressed in adipose tissue where the PPAR γ 2/PPAR γ 1 ratio of messenger RNA is directly correlated with body mass index and where a low-calorie diet downregulates PPAR γ 2 messenger RNA in subcutaneous fat [6]. Several variants in the PPAR γ gene have been identified, with the Pro12Ala variant having been the most extensively examined in epidemiologic studies. A strong association between PPAR γ 12Ala polymorphism and a reduction in type 2 diabetes risk (odds ratio: 0.86, 95 % CI: 0.81–0.90) was described in an updated meta-analysis of 60 studies involving 32,849 subjects with type 2 diabetes mellitus (T2DM) and 47,456 control subjects evaluated by the Human Genome Epidemiology Network [7].

The human PPAR δ , which was cloned from a human osteosarcoma cell library, is located on chromosome 6 at position 6p21.1-p21.2 [8]. In the mouse, where the first PPAR, PPAR α , was identified in 1990 by Issemann and Green [9], PPAR α is found on chromosome 15, PPAR γ is located on chromosome 6 at position E3-F1, while PPAR δ is found on chromosome 17 [10]. In both human and mouse, the PPAR transcript is encoded by six exons (one in the A/B domain,

two in the C domain, one for the hinge region, and two for the ligand binding domain).

PPAR isoforms share a common domain structure as shown in the schematic view in Fig. 19.1. Five domains designated A/B, C, D, E, and F are distinguishable, and each has a different function. The N-terminal A/B domain contains at least one constitutionally active transactivation region (AF-1) and several autonomous transactivation domains (AD) [1]. The specificity of gene transcription is granted by the isoform-specific sequence of the A/B domain of the receptor [11]. Chimeric proteins generated by fusion with the A/B domains of other receptor proteins attenuate the specificity of target gene activation [11]. The DNA binding domain (DBD, C domain) is the most conserved region, which contains a short motif responsible for DNA binding specificity (P-box) on sequences called peroxisome proliferator response elements (PPREs), typically containing the AGGTCA motif.

The D domain, called a hinge, permits the change in shape of PPARs. The C-terminal E/F domain contains the ligand binding domain (LBD) and the AF-2 region for binding coactivators and

corepressors. When activated by ligands, PPARs heterodimerize with another nuclear receptor, the retinoid X receptor, and alter the transcription of target genes after binding to specific PPREs on target genes.

Natural ligands for PPARs are long chain fatty acids, saturated or not, and eicosanoids: 8-HETE (hydroxyeicosatetraenoic acid) and to some extent leukotriene B₄ (LTB₄) for PPAR α ; 9- and 13-HODE (hydroxyoctadecadienoic acid), two 15 lipoxygenase metabolites of linoleic acid, and 15-deoxy PGJ₂ for PPAR γ ; and prostacyclin (PGI₂) for PPAR δ [12–14]. However, tissue concentrations are probably too low for them being the active ligands [15]. A new candidate endogenous ligand for PPAR α in the liver is a glycerophosphocholine esterified with palmitic and oleic acids 16:0/18:1-GPC or POPC (1-palmitoyl,2-oleoyl-sn-glycero-3-phosphocholine hydroxyeicosatetraenoic acid), which was identified in the liver of mice by tandem mass spectrometry [16]. This phosphatidylcholine is displaced from PPAR α by the synthetic agonist Wy14643. Its portal infusion induces dependent gene expression of carnitine palmitoyltransferase I (CPT1) in wild-type mice, but not in PPAR α deficient mice. Recently, two other phosphatidylcholines, DLPC and DUPC (1,2-dilauroyl-sn-glycero-3-phospho-choline and 1,2-(cis-cis-9,12-octadecadienoyl)-sn-glycero-3-phosphatidylcholine, respectively), have been shown to improve glucose control in two mouse models of insulin resistance [17]; however, they did not affect rosiglitazone binding to PPAR γ , and their effects are linked to stimulation of another nuclear receptor liver receptor homologue (LRH)-1.

Synthetic Ligands: From PPAR Activators to PPAR Agonists

PPAR α was first cloned from a mouse liver cDNA library at ICI, the pharmaceutical company which developed clofibrate, the first fibrate [9], and subsequently in humans [2, 18]. Fibrates, which were in clinical use as lipid-lowering agents for 20 years before this discovery, are weak PPAR α agonists, effective on human PPAR

in the micromolar range, explaining the observation that they are given in the range of 100–1,200 mg per day. Fibrates, such as fenofibrate, mainly act via activation of PPAR α in the liver to regulate genes involved in fatty acid oxidation [19]. They were then called PPAR α activators, and their main laboratory effects are to reduce triglycerides and increase high-density lipoprotein (HDL) cholesterol levels. The first potent and selective PPAR α agonist acting in the nanomolar range with clinical data was LY518674, the development of which was stopped in 2007 when phase 2 studies showed no advantage over existing fenofibrate [20].

The link between PPAR γ activation and the thiazolidinedione insulin-sensitizing agents pioglitazone and rosiglitazone was established by researchers at Upjohn and Glaxo in 1994 and 1995, respectively [21, 22]. PPAR γ increases adipocyte differentiation and storage of fat. The short-term marker of PPAR γ activation in plasma is an increase in levels of the adipocytokine adiponectin, which increases insulin sensitivity in liver and muscle [23, 24]. The first animal results with PPAR δ agonists L165041 and GW501516 were reported in 1999 by researchers at Merck and in 2001 at Glaxo [25, 26].

The PPAR Machinery

The PPAR machinery is similar to other nuclear receptors with sequential complexes of coactivators and corepressors with enzymatic activities (for review, see Rosenfeld 2006) [27] and a series of metabolic transformations that turn PPARs toward activation or direct them to degradation (Fig. 19.2). The role of these different proteins, their metabolic transformations, and the concept of selective PPAR modulator are summarized in the next sections. Without ligand the transcription of DNA into messenger RNA is usually repressed by the binding of corepressors on the heterodimer PPAR–RXR, and chromatin is compacted (Fig. 19.3). With the presence of ligand in the ligand binding domain, the structural changes in the AF-2 region permit to replace corepressors by coactivators, to associate remodeling of




Fig. 19.2 PPAR network. Upon activation with ligand, PPAR heterodimerizes with RXR α and activate target genes (transactivation). Phosphorylation has opposite effect transactivation for PPAR α or its inhibition for PPAR γ . Sumoylation of PPAR is associated with transrepression which prevents transcription of NF κ B or AP-1-

dependent inflammatory genes and with a reduction of degradation in the proteasome. CDK5, cyclin-dependent kinase 5; ERK MAPK, mitogen-activated kinase; PKA PKC AMPK, protein kinase A or C and AMP-activated kinase; NCoR, nuclear corepressor; HDAC3, histone deacetylase 3




Fig. 19.3 Corepressor complex: without ligand, PPAR and RXR α are linked to their PPRE direct repeat (AGGTCA n AGGTT) by the DNA binding domain; the corepressors NCoR and SMRT prevent DNA transcrip-

tion. AF1 AF2 ligand-independent transactivation domains 1 and 2; DBD, DNA binding domain; LBD, ligand binding domain; NCoR, nuclear corepressor; SMRT, silencing mediator for retinoid and thyroid hormone

chromatin by acetylation of histones, in order for RNA polymerase to access the DNA and initiate transcription (Fig. 19.4). One important aspect common to PPAR activation is transrepression of inflammatory genes under the control of nuclear

factor kappa B (NF κ B) or activated protein (AP) 1. This transrepression is an indirect effect since there is no PPRE in the promoter. This was shown for PPAR γ on induction of tumor necrosis factor (TNF) α by phorbol myristate acetate in human




Fig. 19.4 Coactivator complex: with fixation of ligands, conformational changes in ligand binding domain permit replacement of corepressors by coactivators, of which the

enzymatic activities acetylate, phosphorylate, or methylate the chromatin allowing access to DNA or RNA polymerase and initiation of transcription into copies of messenger RNA

monocytes/macrophages [28], for PPAR α on human aortic smooth muscle cells and interleukin (IL)-1-induced IL6 expression [29, 30], and for PPAR δ with expression of monocyte chemoattractant protein (MCP)-1 [31]. In human endothelial cells, fenofibrate and L165041, but not rosiglitazone, inhibited TNF α -induced monocyte adhesion, vascular cell adhesion molecule-1 (VCAM-1) expression, and monocyte chemotactic protein-1 (MCP-1) secretion through inhibition of nuclear P65 translocation, necessary for NF κ B activation [32].

PPAR Coactivators and Corepressors

The main PPAR coactivator, or at least the best studied one, is peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1 α) [33]. Through a number of transcription factors, including PPARs, PGC-1 α modulates numerous metabolic pathways in the liver, skeletal and cardiac muscle, and adipose tissue, including gluconeogenesis and glycolysis, fatty acid synthesis, and oxidation. Indeed, PGC-1 α itself is subject to the same modulations as PPAR (see below through phosphorylation, ubiquitination, or sumoylation). Other PPAR coactivators are steroid receptor coactivator 1 (SRC1) and cyclic

adenosine 5'-monophosphate (cAMP) response element binding protein (CBP/P300) which possess histone acetyltransferase activity, leading to the decondensation of chromatin which is necessary for gene transcription.

The main PPAR corepressors, nuclear receptor corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone (SMRT), are associated with histone deacetylase activity which maintain chromatin in a compact state. The role of NCoR was studied by specifically knocking out its gene in mouse adipocytes (AKO) or muscle (MKO). MKO mice were able to run longer than normal mice [34]. AKO mice had higher insulin sensitivity in liver, muscle, and adipose tissue than normal mice, with limited additional effect of rosiglitazone since PPAR γ target genes were already derepressed by NCoR deletion [35]. The effects of rosiglitazone to cause hemodilution were the same in AKO and normal mice. In MKO mice, exercise capacity and mitochondrial oxidation are enhanced by the loss of a transcriptional cofactor in muscle cells through modulation of transcription factors that includes PPAR δ . SMRT is a protein structurally similar to NCoR, which possesses different receptor interaction domains (RID) for different nuclear receptors, called RID2 for PPAR or RXR or RID1 for retinoid acid receptor [36].

Phosphorylation

Phosphorylation of PPAR γ by extracellular signal-related kinase (ERK) 1 at serine 112 inhibits adipogenesis [37]. Phosphorylation of PPAR α on serine residues in the ligand-independent transactivation domain AF-1 in response to insulin increases transcription activity through dissociation of corepressors [38]. HMG-CoA reductase inhibitors (“statins”) have been shown to stimulate PPAR α transcription by reducing its phosphorylation in HepG2 cells, a synergistic effect with fenofibric acid [39]. Transcriptional activation of PPAR α by bezafibrate was dose-dependently increased by statins in human kidney 293T cells. In addition, concomitant administration of fenofibric acid and pitavastatin decreased the transactivation of NF κ B induced by phorbol myristate acetate (PMA) [40]. Data on PPAR δ phosphorylation are limited to the location of predicted consensus phosphorylation sites and inhibition of PPAR δ activation by kinase inhibitors [41].

It was shown recently that phosphorylation of PPAR γ at serine 273 by activated CDK5 leads to a loss of transcription of PPAR γ in adipocytes [42]. The cyclin-dependent kinase (CDK) 5, which is present in the cytoplasm and the nucleus, is activated by phosphorylation at tyrosine 15 within a high glucose milieu and IL1 β , by TNF α , or by high-fat diet. This finding permitted the same authors to discover new small molecules binding to PPAR γ blocking CDK5 serine 273 phosphorylation, like thiazolidinediones (TZDs), with potent antidiabetic activity in insulin-resistant mice fed with a high-fat, high-sugar diet, without causing fluid retention and weight gain [43].

Ubiquitination

Proteins are degraded in the proteasome after fixation on lysine residues of repeated sequences of a small 76AA polypeptide called ubiquitin. In the absence of their ligands, PPARs are rapidly degraded by this process. The degradation of PPAR γ is increased by different TZD ligands [44]; conversely, ubiquitination of PPAR α is reduced transiently with different fibrate ligands

[45], and ubiquitination of PPAR δ is markedly reduced by PPAR δ agonists [46].

Sumoylation

Sumoylation is the attachment of another polypeptide of 101 amino acids called SUMO, for small ubiquitin-like modifier. Sumoylation at a lysine in the ligand binding domain of PPAR γ is the mechanism which converts activation of transcription by rosiglitazone into repression of NF κ B or activator protein (AP) 1 in murine macrophages. This prevents ubiquitination of NCoR to maintain repression of inflammatory genes such as inducible NO synthase [47]. In adipose tissue, sumoylation of PPAR γ , which reduces the effect of rosiglitazone, is increased in the absence of the hepatokine fibroblast growth factor (FGF) 21 [48].

Similarly, sumoylation at lysine 185 has been identified in the hinge region of PPAR α [49]. To date, a potential sumoylation site for PPAR δ has been suggested on lysine 185, as for PPAR α .

Posttranslational regulation of PPARs by different patterns of mono- or polyubiquitination, as well as by mono- or polysumoylation, has been recently reviewed by Wadosky and Willis [50]. This review also reports that the coreceptor RXR α and the coactivators PGC-1 α can be ubiquitinated or sumoylated, adding to the complexity of these regulatory processes.

Acetylation

Acetylation and deacetylation of genes are major processes affecting gene expression through decondensation and recondensation of chromatin. It also affects proteins. The first nuclear receptors shown to be acetylated were the androgen–estrogen receptors; this has not been shown clearly for PPAR [51]. However, their key coactivator PGC-1 α is inactivated by acetylation in high-energy states or deacetylated by sirtuin 1 in low-energy states [52]. The nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases or sirtuins by interacting with PPARs and their coactivators thus provide a new level of complexity to the regulation of nuclear receptors [53].

Partial Agonists or SPPARMs

A partial agonist is a ligand that induces a sub-maximal response even at full receptor occupancy. It can also reduce the full PPAR γ agonist response. For instance, in comparison with rosiglitazone, troglitazone is a full agonist on murine 3T3L1 adipocytes but a partial agonist in muscle C2C12 myotubes and HEK293T kidney cells [54]. Olefsky proposed to name selective PPAR modulators (SPPARMs); such products differ from full agonists by differential regulation of target genes [55]. SPPARMs are designed to separate efficacy and adverse effect dose–response curves. This concept was already developed in nuclear receptor pharmacology, with selective estrogen receptor modulators (SERMs), such as tamoxifen or raloxifene, which recruit corepressors such as NCoR to the AF-2 region, whereas estradiol recruits coactivators such as the glucocorticoid receptor-interacting protein 1 (GRIP1) [56] or with selective vitamin D modulators such as paricalcitol with differential recruitment of coactivators than calcitriol, the active form of vitamin D [57].

Increasing concentrations or doses with full PPAR γ agonists lead to greater efficacy but greater adverse events, such as weight gain and volume expansion.

PPAR γ partial agonists such as balaglitazone or INT131 displace a full agonist such as rosiglitazone. Metaglidasen, the (–) stereoisomer of halofenate, tested in the 1990s as a lipid-lowering agent, is another selective partial PPAR γ modulator and is still in clinical development for its uricosuric activity. They bind the same pocket as TZDs, which is required to block PPAR γ phosphorylation, but induce different conformational changes in PPAR γ , leading to different recruitment of coactivator/corepressor. As an example, INT131 induces less recruitment of DRIP205 (vitamin D-interacting protein 205), a coactivator involved in lipid accumulation than rosiglitazone or pioglitazone in HEK cells [58]. The same finding was reported with fibrates: gemfibrozil induced less recruitment of DRIP205 than fenofibrate and behaves as a partial agonist to increase apoA-I activation. This translated in a comparative trial in dyslipidemic patients to a larger increase in apoA-I

levels, a protective apoprotein in HDL, with fenofibrate than with gemfibrozil [59].

Effects of PPAR Agonists in Diabetes

This review is limited to PPAR activators or agonists which entered clinical development in diabetes and/or dyslipidemia (Table 19.1). Few PPAR antagonists were synthesized and they were not developed for the treatment of diabetes [60]. GW6471, a potent PPAR α antagonist, is used as a pharmacological agent to test whether an effect is PPAR dependent or PPAR independent. GW9662 is a PPAR γ antagonist which promotes the recruitment of NCoR. Finally, GSK0660 and GSK3787 are PPAR δ antagonists for pharmacological use.

The organs implicated in glucose control are listed in Table 19.2. With their direct effects on gene expression and their indirect effects on inflammation, and according to their tissue distribution, PPARs affect most of these organs, beyond the liver for PPAR α , the adipose tissue for PPAR γ , and the skeletal muscle for PPAR δ . In the kidney, they have different locations: PPAR α is located mainly in the proximal tubule, the medullary thick ascending limb, and in the mesangium; PPAR γ in the distal medullary collecting duct and glomeruli; and PPAR δ in a diffuse fashion as in other organs [62]. In the brain, the interplay of PPAR subtypes has been shown in cultures of astrocytes, where the three subtypes are present. Combined application of PPAR γ and PPAR δ activators increased cyclooxygenase 2 expression induced by lipopolysaccharide, whereas the additional application of a PPAR α agonist abolished this effect [63].

In the pancreas, the three PPARs are expressed in pancreatic β cells. PPAR α modulates fatty acid oxidation and PPAR γ directs them toward esterification. Although PPAR δ is the most abundant PPAR in the pancreas at the mRNA and the protein level, until recently its effects on fatty acid oxidation have been less well studied [64]. PPAR δ activation increases fatty acid oxidation and to a larger extent than PPAR α activation. In the pancreas, fatty acids acutely potentiate glucose-stimulated insulin secretion (GSIS), but

Table 19.1 Phase of clinical development reached by PPAR agonists

	PPAR α	PPAR γ	PPAR α/γ	PPAR δ	Pan-PPAR
Marketed	Bezafibrate Ciprofibrate Fenofibrate Gemfibrozil Clinofibrate Etofibrate	Pioglitazone Rosiglitazone			
No more marketed	Clofibrate	Troglitazone			
Phase 3		Balaglitazone Metaglidase ^a Rivoglitazone ^a Ciglitazone Farglitazar ^b	Aleglitazar ^d Lobeglitazone Muraglitazar Ragaglitazar Tesaglitazar Imiglitazar MK767		
Phase 2	K877 ZYH7 AVE8134 GW590735 KRP-105 LY518674 CP778875	INT131 MBX2044 FK614	Cevoglitazar Naveglitazar Sipoglitazar	MBX8025 GW501516 GW0742 L165041	GFT505 ^c Chiglitazar Indeglitazar Sodelglitazar Netoglitazone

^aDiscontinued in diabetes

^bDiscontinued in hepatic fibrosis (McHutchison et al., 2010) [61]

^cPPAR α/δ

^dWithdrawn from clinical development in July 2013

Table 19.2 Organs implicated in glucose control

	PPAR α	PPAR γ	PPAR δ
Liver	Increase in fat oxidation and apoA-1 increase insulin sensitivity	Decrease in steatosis Increase insulin sensitivity	
Skeletal muscle		Increase insulin sensitivity	Increase in fat oxidation and energy expenditure
Adipose tissue	Reduction in inflammatory adipocytokines	Increase in adipocyte differentiation and adiponectin release	
Pancreas			Amplification of glucose- induced insulin secretion
Gut		Anti-inflammatory	Increase in GLP1 production
Vascular wall	Increase in NO synthesis		

their chronic exposure elevates basal insulin secretion and alters GSIS, a phenomenon called lipotoxicity.

Discordant results are reported in the literature with PPAR α or PPAR γ agonists. PPAR α was described to potentiate and PPAR γ to attenuate GSIS in INS-1E cells, an immortalized insulinoma rat cell line [65]. On the contrary, in vivo, the PPAR α agonist fenofibrate impaired GSIS in neonatal rats receiving monosodium glutamate to induce obesity, while pioglitazone, a PPAR γ agonist, increased it in db/db mice [66, 67].

This discordance might be explained by the low expression level of PPAR γ in INS-1E cells.

Activation of PPAR δ by unsaturated FAs or a synthetic ligand enhanced GSIS in primary rat islets or INS-1E cells without affecting basal insulin secretion [64]. In order to maintain β cell function, PPAR δ would play a role of lipid sensor to adjust the mitochondrial fatty acid oxidation. It was recently suggested that 4-hydroxynonenal (4-HNE) was one endogenous activating ligand of PPAR δ [68]. The level of reactive oxygen species (ROS), such as 4-HNE,

is essential to β cell function, as low-level ROS production increases glucose-induced insulin secretion, whereas high levels of ROS can induce β cell apoptosis.

GSIS is also linked to influx of calcium ions to the cytosol induced by depolarization from the voltage-dependent Ca^{++} channel. In INS-1 cells, the sarco-endoplasmic reticulum Ca^{++} ATPase (SERCA2) pump maintains intracellular Ca^{++} homeostasis, in particular, a high Ca^{++} level in the endoplasmic reticulum. The expression of this pump is decreased in animal models of diabetes and in diabetic human islets. Pioglitazone directly increases expression of SERCA2 through transcription of the gene and indirectly through prevention of CDK5-induced phosphorylation of PPAR γ [69]. This experiment suggests that blocking CDK5 could permit to dissociate positive effects on glucose homeostasis from other effects from PPAR γ agonists.

Effects of PPAR Agonists in Type 1 Diabetes

Clinical studies with PPAR agonists in type 1 diabetes (T1DM) are limited to their effects on lipid or glucose markers. One placebo-controlled randomized study was conducted with fenofibrate in 44 patients with T1DM to assess its effect alone or in combination with vitamin E for 8 weeks on copper-induced oxidation of LDL and VLDL particles [70]. The lag time of oxidation was significantly prolonged by fenofibrate 200 mg + vitamin E 400 IU. A placebo-controlled randomized study is in the planning stage to evaluate the effects of fenofibrate on progression of diabetic retinopathy in 400 adults with T1DM (<http://clinicaltrials.gov/ct2/show/NCT01320345>) [71]. The lipid-modifying effects of bezafibrate in T1DM were evaluated in earlier placebo-controlled studies [72, 73]. Of note, this fibrate, now considered as an archetype pan-PPAR agonist in transactivation assays, did not improve HbA1c after 3 months of treatment [40, 74].

Three placebo-controlled randomized studies have been reported with TZDs in T1DM patients on insulin therapy, with modest insulin-sparing effects as compared to those observed in T2DM.

In 50 overweight adults with T1DM, an 8-month intervention to achieve glycated hemoglobin level of 7.0 % required an 11 % increase in the daily dose of insulin in the placebo group, but no change in the rosiglitazone group [75]. In 36 T1DM adolescents aged 10–18 years, the dose of insulin was increased by 9 % with placebo and reduced by 6 % with rosiglitazone after 6 months of treatment, with HbA1c remaining stable around 8.5 % [76]. In 60 lean T1DM patients aged 14 years or more, 6-month treatment with pioglitazone was associated with a significant decrease in HbA1c (0.2 %) and in postprandial glucose levels (0.7 mmol/L) in the intervention group only, with no changes in insulin doses [77]. In patients with slowly progressive T1DM, diagnosed by the presence of glutamic acid decarboxylase (GAD) antibodies, an insulin-requiring state defined by HbA1c and post-glucose C-peptide levels was reached at 4 years in 4/4 subjects randomized to pioglitazone as compared to 1/5 subjects randomized to metformin [78]. Thus, the effects of TZD in T1DM sharply differ from those reported for T2DM prevention with troglitazone in TRIPOD [79], rosiglitazone in DREAM [80], and, more recently, pioglitazone in ACT-NOW [81] and from their effects on glucose control in people with established T2DM.

Effects of PPAR Agonists in Type 2 Diabetes and Dyslipidemia

For the treatment of T2DM, the first TZD PPAR γ agonist troglitazone was introduced in the USA in October 1997 and was withdrawn in March 2000 for hepatic toxicity. Rosiglitazone and pioglitazone were introduced in the USA in 1999 and in Europe in 2000. In Japan, pioglitazone was introduced in 1999 and rosiglitazone in 2003. The effects of pioglitazone on macrovascular events in 5,238 T2DM patients were reported in 2005 [82]. Although the study primary end point was not reached, there was a significant 16 % reduction in the main secondary end point, which included death from any cause, acute non-fatal myocardial infarction, or stroke. The effect of TZDs on diabetes control and the controversy about their hazard on cardiovascular events have

been the subject of numerous reviews in the last 5 years [83–85].

The first request for approval of a PPAR α/γ dual agonist, muraglitazar, was submitted to the Food and Drug Administration (FDA) for registration but was withdrawn in May 2006 after a combined analysis of clinical studies indicated an increased cardiovascular risk [86]. Such an increase in cardiovascular risk led to the suspension of registration of rosiglitazone in Europe in September 2010 and severe limitations to its use in the USA. Finally, in June 2011, pioglitazone was withdrawn from some European markets due to increased risk of bladder tumors, a decision not endorsed by the European Medicines Agency.

Discontinuation of the development of PPAR agonists occurred for multiple reasons: toxicity of the compound (vascular or bladder tumors in rodents with MK767 or ragaglitazar, respectively), long duration of development, clinical adverse events, expectation not to be better than existing drugs, and stopping of development efforts in the cardiometabolic domain. In particular, the FDA requested in July 2004 that 2-year rodent carcinogenicity studies be completed and reviewed before proceeding to phase 3 studies of more than 6-month duration. This decision was made after the evaluation of carcinogenicity in rodents for 11 PPAR agonists, with the observation of hemangioma/hemangiocarcinoma with 8/11 compounds and urinary bladder/renal pelvic transitional cell carcinomas with 5/6 PPAR α/γ dual agonists and pioglitazone (www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf) [87]. In addition, the FDA requested in December 2008 that new antidiabetic agents had to demonstrate through randomized, prospective clinical trials that they do not increase risk for cardiovascular events (www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf) [88]. The thiazolidinedione intervention with vitamin D evaluation (TIDE) study, a large intervention study to assess the effect of the existing TZDs pioglitazone and rosiglitazone on cardiovascular events, planned in 16,000 T2DM patients at risk of CVD events was initiated in 2009 but stopped by the FDA 1 year later leaving

uncertainty about the risks and benefits from TZDs (TIDE 2012) [89]. The authors stated that, had this study been initiated earlier, it would have provided clear evidence regarding the efficacy and safety of rosiglitazone and pioglitazone.

Currently the number of PPAR agonists in phase 2 or phase 3 of clinical development in diabetes and/or dyslipidemia has been markedly reduced as compared to the mid-2000s (Table 19.3).

The most promising was aleglitazar, a PPAR α/γ dual agonist with a large intervention study ALECARDIO underway in 7,000 T2DM patients with a recent acute coronary syndrome. They will be randomized to aleglitazar 150 μg or placebo and followed until there have been 950 primary events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) and for a minimum of 2.5 years for each participant (<http://clinicaltrials.gov/ct2/show/NCT01042769>) [90]. The dose of 150 μg was thought to offer glycemic control equal to pioglitazone and a more favorable effect on the lipid profile. The PPAR α component is responsible for a dose-related increase in circulating creatinine levels, with a 17 % reduction in measured glomerular filtration rate at the 600 μg dose [91, 92]. Another PPAR α/γ dual agonist, lobeglitazone or CKD-501, is currently recruiting T2DM patients in a 6-month comparative trial with pioglitazone (<http://clinicaltrials.gov/ct2/show/NCT01106131>) [93].

Two PPAR α agonists are in phase 2 of development for treatment of dyslipidemia in comparison with fenofibrate (K877 Kowa and ZYH7 Zydus <http://clinicaltrials.gov/ct2/results?term=01539616>) [94]. The PPAR γ SPPARMs balaglitazone and INT131 appear to be as effective as pioglitazone on HbA1c levels but cause less weight gain in 6-month trials (<http://clinicaltrials.gov/ct2/show/NCT00631007>) [95, 96].

Clinical studies with PPAR δ activators have been limited to short-term mechanistic studies. In healthy volunteer and in moderately obese subjects with dyslipidemia, GW501516 10 mg once daily (od) for 2 weeks reduced fasting and postprandial triglyceride (TG) levels by 30 %, liver fat measured by magnetic resonance imaging by 20 %, and urinary isoprostane levels, a marker of

Table 19.3 Effects of recent PPAR agonists on lipids, glycated hemoglobin, and weight

	Design/PPAR agonist	Study groups	HDL-C %change	TG %change	HbA1c %change	Weight change
Nissen [20]	R,DB,6PG, 12 weeks <i>N</i> =309 dyslipidemic LY518674 PPAR α	Placebo	-1 %	+1 %	N/A	N/A
		Feno 200 mg	+14 %	-33 %		
		LY 10 μ g	+10 %	-36 %		
		LY 25 μ g	+16 %	-41 %		
		LY 50 μ g	+11 %	-42 %		
		LY 100 μ g	+2 %	-35 %		
NCT00631007 [96]	R,DB,6PG, 24 weeks <i>N</i> =367 T2DM on metformin/sulfonylurea INT-131 PPAR γ	Placebo	N/A	N/A	-0.1 %	0/61
		Pio 45 mg			-0.9 %	6/60
		0.5 mg			-0.3 %	0/60
		1 mg			-0.6 %	2/61
		2 mg			-0.9 %	1/63
		3 mg			-1.0 %	4/61
Henriksen [95]	R,DB,4PG, 26 weeks <i>N</i> =409 T2DM on insulin Balaglitazone Partial PPAR γ	Placebo	N/A	N/A	+0.7 %	+0.5 kg
		Pio 45 mg			-0.5 %	+5 kg
		Bala 10 mg			-0.3 %	+3.5 kg
		Bala 20 mg			-0.4 %	+5 kg
Henry [91]	R,DB,6PG, 16 weeks <i>N</i> =332 T2DM Aleglitazar PPAR α/γ SYNCHRONY	Placebo	+4 %	+15 %	+0.4 %	-0.8 kg
		Pio 45 mg	+16 %	-10 %	-0.3 %	+1.1 kg
		Ale 50 μ g	+12 %	-15 %	0.0 %	-0.2 kg
		Ale 150 μ g	+25 %	-30 %	-0.45 %	+0.5 kg
		Ale 300 μ g	+28 %	-35 %	-0.7 %	+1.2 kg
		Ale 600 μ g	+27 %	-40 %	-1.1 %	+2.7 kg
Sanwald- Ducray [102]	R,DB,7PG, 6 weeks <i>N</i> =65 T2DM Aleglitazar PPAR α/γ	Placebo	+3 %	+10 %	N/A	-0.2 kg
		Ale 20 μ g	-3 %	-5 %		0.0 kg
		Ale 50 μ g	+15 %	-15 %		-0.2 kg
		Ale 100 μ g	+25 %	-20 %		-0.7 kg
		Ale 300 μ g	+18 %	-35 %		-0.2 kg
		Ale 600 μ g	+20 %	-25 %		+1.1 kg
		Ale 900 μ g	+15 %	-35 %		+1.5 kg
NCT00196989 GSK [101]	R,DB,7PG, 16 weeks <i>N</i> =352 T2DM on diet and/or metformin GW677954 Sodelglitazar PPAR $\alpha/\gamma/\delta$	Placebo	-0.5 %	-9 %	-0.4 %	N/A
		Pio 30/45 mg	+10 %	-10 %	-1.1 %	
		GW 2.5 mg	+11 %	-12 %	-0.35 %	
		GW 5 mg	+15 %	-27 %	0.0 %	
		GW 10 mg	+18 %	-34 %	-0.3 %	
		GW 15 mg	+16 %	-26 %	-0.2 %	
		GW 20 mg	+18 %	-25 %	-0.2 %	
Bays [99]	R,DP,6PG, 8 weeks <i>N</i> =181 dyslipidemia MBX-8025 PPAR δ	Placebo	+1 %	-5 %	N/A	Unchanged
		Atorva 20 mg M 50 mg	+2 %	-18 %		
		M 100 mg	+10 %	-32 %		
		A20+M 50 mg	+13 %	-33 %		
		A20+M 100 mg	+13 %	-35 %		
			+2 %	-31 %		
Cariou [100]	R,DB, 2PG, 5 weeks <i>N</i> =47 prediabetes GFT505 PPAR α/δ	Placebo	-3 %	-4 %	N/A	N/A
		GFT505 80 mg	+7 %	-32 %		

R randomized, *DB* double blind, *PG* parallel group, *Atorva* atorvastatin, *Feno* fenofibrate, *N/A* not available, *Pio* pioglitazone, *T2DM* type 2 diabetes. If not provided, percent changes are estimated from figures or calculated from actual means before and after treatment

oxidative stress, by 30 %. In a skeletal muscle biopsy of the thigh, the expression of carnitine palmitoyltransferase 1b, which permits fatty

acid to enter the mitochondria, was increased suggesting increased fat oxidation [97]. In a randomized, placebo-controlled, crossover trial,

13 obese dyslipidemic subjects received GW501516 2.5 mg once daily for 6 weeks. The GW501516 reduced apoC-III production, increased VLDL-apoB catabolism, and increased apoA-II production and HDL-cholesterol (HDL-C) levels [98]. MBX8025, another specific PPAR δ agonist, was recently reported to reduce TG and increase HDL-C levels alone or in combination with a statin in 181 dyslipidemic patients treated for 8 weeks [99]. GFT505 is a PPAR α/δ currently in phase 2 with a recently completed 3-month study in T2DM [100]. The first pan-PPAR agonist advanced to phase 2 was GW677954 or sodelglitazar which was discontinued from clinical development due to safety concerns. Chigliitazar is another pan-PPAR agonist in development in China.

Conclusion and Perspectives

The pharmacology of PPARs, one family of nuclear receptors, is extremely complex as it regulates energy stores in major organs through modulation of genes in lipid and carbohydrate metabolism as well as adaptation to stress, fasting, and feeding. The natural ligands for PPARs are fatty acids and prostaglandins. Their first synthetic ligands are fibrates for PPAR α ; thiazolidinediones for PPAR γ ; within the last 10 years description of few PPAR δ agonists; and then dual and pan-PPAR agonists. Most of these well-designed products have been discontinued from clinical development for various reasons from animal toxicity and clinical safety to no advantage over existing drugs or hurdles to substantiate it. Currently, the most advanced new PPAR agonist is aleglitazar, a dual PPAR α/γ agonist, which is being evaluated for the prevention of cardiovascular events in people with type 2 diabetes and a recent acute coronary syndrome. The prevention and treatment of microvascular events, as shown with fenofibrate, now in clinical use for 40 years, should represent another area of research for new products. The anti-inflammatory effects of PPAR agonists have been well documented in animal experiments, although their potential in human disease is yet to be demonstrated.

The search for natural PPAR ligands has been encouraged by the recent discovery that phosphatidylcholine derivatives can activate PPAR α and should continue for other PPARs and orphan nuclear receptors.

References

- Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocr Rev.* 1999;20:649–88.
- Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. *Biochemistry.* 1993;32:5598–604.
- Lazar MA, Chin WW. Nuclear thyroid hormone receptors. *J Clin Invest.* 1990;86:1777–82.
- Mattei MG, Rivière M, Krust A, Ingvarsson S, Vennström B, Islam MQ, et al. Chromosomal assignment of retinoic acid receptor (RAR) genes in the human, mouse, and rat genomes. *Genomics.* 1991; 10:1061–9.
- Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. *Gene Expr.* 1995;4:281–99.
- Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues. *J Clin Invest.* 1997;99:2416–22.
- Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. *Am J Epidemiol.* 2010;171:645–55.
- Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. *Mol Endocrinol.* 1992;6:1634–41.
- Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature.* 1990;347:645–50.
- Youssef J, Badr M. Role of peroxisome proliferator-activated receptors in inflammation control. *J Biomed Biotechnol.* 2004;3:156–66.
- Hummasti S, Tontonoz P. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis. *Mol Endocrinol.* 2006;20:1261–75.
- Devchand P, Keller H, Peters H, Vasquez M, Gonzalez F, Wahli W. The PPAR alpha-leukotriene B4 pathway to inflammation control. *Nature.* 1996;384:39–43.

13. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ . *Proc Natl Acad Sci USA*. 1997;94:4318–23.
14. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ . *Proc Natl Acad Sci USA*. 1997;94:4312–7.
15. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. *J Med Chem*. 2000;43:527–50.
16. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RV, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPAR α in liver. *Cell*. 2009;138:476–88.
17. Lee JM, Lee YK, Mamrosh JL, Busby SA, Griffin PR, Pathak MC, et al. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. *Nature*. 2011;474:506–12.
18. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. *J Steroid Biochem Mol Biol*. 1994;51:157–66.
19. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. *Biochim Biophys Acta*. 1996;1302:93–109.
20. Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlane E, Wang MD, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. *JAMA*. 2007;297:1362–73.
21. Harris PK, Kletzien RF. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. *Mol Pharmacol*. 1994;45: 439–45.
22. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem*. 1995;270:12953–6.
23. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocytes-derived bioactive substances. *Ann N Y Acad Sci*. 1999;892:146–54.
24. Wagner JA, Wright EC, Ennis MM, Prince M, Kochan J, Nunez DJ, et al. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. *Clin Pharmacol Ther*. 2009;86:619–25.
25. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, et al. Novel peroxisome proliferator-activated receptor (PPAR) γ and PPAR δ ligands produce distinct biological effects. *J Biol Chem*. 1999;274:6718–25.
26. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci USA*. 2001;98:5306–11.
27. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. *Genes Dev*. 2006;20:1405–28.
28. Jiang C, Ting AT, Seed B. PPAR- γ agonists inhibit production of monocyte inflammatory cytokines. *Nature*. 1998;391:82–6.
29. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. *Nature*. 1998;393:790–3.
30. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1. *J Biol Chem*. 1999;274: 32048–54.
31. Lee C-H, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM. Transcriptional repression of atherogenic inflammation: modulation by PPAR delta. *Science*. 2003;302:453–7.
32. Rival Y, Benéteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, et al. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. *Eur J Pharmacol*. 2002;435:143–51.
33. Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1 α , a nodal regulator of mitochondrial biogenesis. *Am J Clin Nutr*. 2011;93:884S–90.
34. Yamamoto H, Williams EG, Mouchiroud L, Cantó C, Fan W, Downes M, et al. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. *Cell*. 2011;147:827–39.
35. Li P, Fan W, Xu J, Lu M, Yamamoto H, Auwerx J. Adipocyte NCoR knockout decreases PPAR γ phosphorylation and enhances PPAR γ activity and insulin sensitivity. *Cell*. 2011;147:815–26.
36. Reilly SM, Bhargava P, Liu S, Gangl MR, Gorgun C, Nofsinger RR, et al. Nuclear receptor corepressor SMRT regulates mitochondrial oxidative metabolism and mediates aging-related metabolic deterioration. *Cell Metab*. 2010;12:643–53.
37. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma. *Science*. 1996; 274:2100–3.
38. Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, Pernin A, Takeshita A, Chin WW, et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. *J Biol Chem*. 1999;274:10505–10.

39. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. *J Clin Invest.* 2001;107:1423–32.
40. Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, et al. Fibrate and statin synergistically increase the transcriptional activities of PPAR α /RXR α and decrease the transactivation of NF κ B. *Biochem Biophys Res Commun.* 2002;290:131–9.
41. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. *Biochim Biophys Acta.* 2007;1771:952–60.
42. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR γ by Cdk5. *Nature.* 2010;466:451–7.
43. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. Antidiabetic actions of a non-agonist PPAR γ ligand blocking Cdk5-mediated phosphorylation. *Nature.* 2011;477:477–81.
44. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. *J Biol Chem.* 2000;275:18527–33.
45. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. *J Biol Chem.* 2002;277:37254–9.
46. Genini D, Catapano CV. Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor δ activity. *J Biol Chem.* 2007;282:11776–85.
47. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. *Nature.* 2005;437:759–63.
48. Dutchak PA, Katafuchi T, Bookout AL, Choi JL, Yu RT, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor-21 regulates PPAR γ activity and the antidiabetic actions of thiazolidinediones. *Cell.* 2012;148:556–67.
49. Pourcet B, Pineda-Torra I, Derudas B, Staels B, Glineur C. SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. *J Biol Chem.* 2010;285:5983–92.
50. Wadosky KM, Willis MS. The story so far: post translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. *Am J Physiol Heart Circ Physiol.* 2011;302:H515–26.
51. Wang C, Powell MJ, Popov VM, Pestell RG. Acetylation in nuclear receptor signaling and the role of sirtuins. *Mol Endocrinol.* 2008;22:539–45.
52. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. *Cell Metab.* 2006;3:429–38.
53. Finkel T, Deng CX, Mostoslavsky P. Recent progress in the biology and physiology of sirtuins. *Nature.* 2009;460:587–91.
54. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, et al. Differential activation of peroxisome proliferator-activated receptor-[gamma] by troglitazone and rosiglitazone. *Diabetes.* 2000;49:539–47.
55. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. *J Clin Invest.* 2000;106:467–72.
56. Shang Y, Hu X, DiRenzo J, Lazar MA, Brow M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell.* 2000;103:843–52.
57. Issa LL, Leong GM, Sutherland RL, Eisman JA. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. *J Bone Miner Res.* 2002;17:879–90.
58. Higgins LS, Mantzoros CS. The development of INT131 as a selective PPAR γ modulator: approach to a safer insulin sensitizer. *PPAR Res.* 2008. doi:10.1155/2009/936906.
59. Duez H, Lefebvre B, Poulain P, Pineda Torra I, Percevault F, Luc G, et al. Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation. *Arterioscler Thromb Vasc Biol.* 2005;25:1–7.
60. Pirat C, Farce A, Lebegue N, Renault N, Furman C, Millet R, et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. *J Med Chem.* 2012 Jan 19. doi:10.1021/jm101360s.
61. McHutchison J, Goodman Z, Patel K, Makhlof H, Rodriguez-Torres M, Shiffman M. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. *Gastroenterology.* 2010;138:1365–73.
62. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic target in renal disease. *Kidney Int.* 2001;60:14–30.
63. Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels. *Mol Pharmacol.* 2009;76:414–24.
64. Ravnskjaer K, Frigerio F, Boergesen M, Nielsen T, Maechler P, Mandrup S. PPAR delta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction. *J Lipid Res.* 2010;51:1370–9.
65. Ravnskjaer K, Boergesen M, Rubi B, Larsen JK, Nielsen T, Fridriksson J, et al. Peroxisome

- proliferator-activated receptor α (PPAR α) potentiates, whereas PPAR γ attenuates, glucose-stimulated insulin secretion in pancreatic β cells. *Endocrinology*. 2005;146:3266–76.
66. Liu S, Lui Q, Li L, Huan Y, Sun S, Shen Z. Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is it a latent disadvantage? *J Transl Med*. 2011;9:176.
 67. Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K, et al. Combination therapy with PPAR γ and PPAR α agonists increases glucose-stimulated insulin secretion in db/db mice. *Am J Physiol Endocrinol Metab*. 2003;284:E966–71.
 68. Cohen G, Riahi Y, Shamni O, Guichardant M, Chatgialiloglu C, Ferreri C, et al. Role of lipid peroxidation and PPAR- δ in amplifying glucose-stimulated insulin secretion. *Diabetes*. 2011;60:2830–42.
 69. Kono T, Ahn G, Moss DR, Gann L, Zarain-Herzberg A, Nishiki Y, et al. PPAR γ activation restores pancreatic islet SERCA2 levels and prevents β -cell dysfunction under conditions of hyperglycaemic and cytokine stress. *Mol Endocrinol*. 2012;26:257–71.
 70. Engelen W, Manuel-y-Keenoy B, Vertommen J, De Leeuw I, Van Gaal L. Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus. *Diabetes Metab*. 2005;31:197–204.
 71. A trial in adults with type 1 diabetes mellitus evaluating the effects of fenofibrate versus placebo on macular thickness and volume (FAME 1 EYE). Available from: <http://clinicaltrials.gov/ct2/show/NCT01320345>. Last Accessed 8 Mar 2012.
 72. Winocour PH, Durrington PN, Bhatagnar D, Ishola M, Arrol S, Lahor BC, Anderson DC. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins and fibrinogen in hypercholelipidaemic type 1 diabetes. *Diabet Med*. 1990;7:736–43.
 73. Winocour PH, Durrington PN, Bhatagnar D, Ishola M, Mackness M, Arrol S, Anderson DC. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia. *Atherosclerosis*. 1992;93:83–94.
 74. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. *Cardiovasc Diabetol*. 2005;4:14. doi:10.1186/475-2840-4-14.
 75. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. *Diabetes Care*. 2005;28:1562–7.
 76. Stone ML, Walker JL, Chisholm D, Craig ME, Donaghue KC, Crock P, et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. *Pediatr Diabetes*. 2008;9(part 1):326–34.
 77. Bhat R, Bhansali A, Bhadada S, Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. *Diabetes Res Clin Pract*. 2007;78:349–54.
 78. Shimada A, Shigihara T, Okubo Y, Katsuki T, Yamada Y, Oikawa Y. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. *Diabetes Metab Res Rev*. 2011;27:951–3.
 79. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. *Diabetes*. 2002;51:2796–803.
 80. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose. *Lancet*. 2006;368:1096–105.
 81. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA. Pioglitazone for diabetes prevention in impaired glucose tolerance. *N Engl J Med*. 2011;364:1104–15.
 82. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. *Lancet*. 2005;366:1279–89.
 83. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. *Drugs*. 2010;70:1945–61.
 84. Krentz AJ. Rosiglitazone: trials, tribulations and termination. *Drugs*. 2011;71:123–30.
 85. Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. *Am J Med*. 2012;125:126–33.
 86. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. *JAMA*. 2005;294:2581–6.
 87. FDA guidance for the industry. Diabetes mellitus. Developing drugs and therapeutic biologics for treatment and prevention. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf. Accessed 17 Feb 2012.
 88. FDA guidance for industry. Diabetes Mellitus. Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 Diabetes. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed 17 Feb 2012.
 89. The TIDE Trial Investigators. Design, history and results of the thiazolidinedione intervention with

- vitamin D evaluation (TIDE) randomised controlled trial. *Diabetologia*. 2012;55:36–45.
90. A study with alogliptaz in patients with a recent acute coronary syndrome and type 2 diabetes. Available from: <http://clinicaltrials.gov/ct2/show/NCT01042769>. Last Accessed 8 Mar 2012.
 91. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor- α / γ agonist alogliptaz on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. *Lancet*. 2009;374:126–35.
 92. Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, et al. Effects of high dose alogliptaz on renal function in patients with type 2 diabetes. *Int J Cardiol*. 2011;151(2):136–42.
 93. Efficacy and safety of CKD-501 versus pioglitazone when added to metformin. Available from: <http://clinicaltrials.gov/ct2/show/NCT01106131>. Last Accessed 8 Mar 2012.
 94. A clinical trial to evaluate the safety and efficacy of ZYH7 compared with fenofibrate in patients with dyslipidemia. Available from: <http://clinicaltrials.gov/ct2/results?term=01539616>. Last Accessed 1 Mar 2012.
 95. Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ. Efficacy and safety of the PPAR γ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. *Diabetes Metab Res Rev*. 2011;27:392–401.
 96. A placebo-controlled safety and efficacy study of INT131 besylate in type 2 diabetes with an active comparator. Available from: <http://clinicaltrials.gov/ct2/results?term=00631007>. Last Accessed 1 Mar 2012.
 97. Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, et al. Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. *Diabetes*. 2008;57:332–9.
 98. Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)- δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. *J Clin Endocrinol Metab*. 2011;96:E1568–76.
 99. Bays HE, Schwartz S, Littlejohn T 3rd, Kerzner B, Krauss RM, Karpf DB. MBX-8025, a novel peroxisome proliferator receptor- δ agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. *J Clin Endocrinol Metab*. 2011;96:2889–97.
 100. Cariou B, Zaïr Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. *Diabetologia*. 2011;34:2008–14.
 101. A multicenter, randomized, double-blind, double-dummy, parallel-group, placebo-controlled, Study to Evaluate Efficacy, Safety and Tolerability of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 mg Once A Day) as a Monotherapy (Diet and/or exercise treated) or as an Add-On to Metformin for 16 Weeks Duration in Subjects with Type 2 Diabetes Mellitus. Study No.: ADG20001, available on: gsk-clinicalstudyregister.com/files/20462.pdf - 2010-.
 102. Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L. Pharmacokinetics, pharmacodynamics, and tolerability of alogliptaz in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. *Clin Pharmacol Ther*. 2010;88:197–203.